Magnesium sulfate improves some risk factors for atherosclerosis in patients suffering from one or two coronary artery diseases: A double-blind clinical trial study

Abstract

Purpose: Given the beneficial effect of MgSO4 on the cardiovascular system, this study was designed to investigate the effect of MgSO4 administration on suppressing some athero-sclerotic risk factors in moderate coronary artery disease patients with one or two athero-sclerotic vessels. Patients and Methods: In a randomized double-blind placebo-controlled clinical trial study, 64 patients with moderate coronary artery disease (55–69% stenosis) were selected according to angiography findings. Patients were divided into four groups including patients with one or two atherosclerotic vessels treated with MgSO4 (Mg-treated-VR1, Mg-treated-VR2, respectively), placebo treated patients with one or two atherosclerotic vessels (Control-VR1, Control-VR2, respectively). The patients received either placebo or MgSO4 supplement capsule containing 300 mg MgSO4 for six months on a daily basis. ESR, Ca/Mg ratio, urine Mg level, serum Mg, fibrinogen, homocysteine, uric acid, Na, K, Ca, CRP, T3, T4, TSH, BUN, and Cr concentrations were measured at baseline and every three months. Results: Serum T3, Ca, K, homocysteine, CRP, and Mg concentrations were significantly improved in Mg-treated groups compared to placebo groups. Conclusion: The results of this study showed that despite the slight change in serum magnesium level, oral administration of MgSO4 for six months could slightly reduce the serum levels of some inflammatory and vascular factors in moderate coronary artery disease patients.